Coherus Oncology, Inc. Common Stock
CHRSCoherus BioSciences, Inc. is a biotechnology company focused on developing and commercializing biosimilar and biologic therapies. The company aims to provide affordable alternatives to existing biologic treatments in areas such as oncology, immunology, and ophthalmology. Coherus focuses on advanced biologic products and has a portfolio that includes biosimilars for popular reference drugs.
Company News
Coherus Oncology and Zumutor Biologics announced a Phase 1 clinical collaboration to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, in patients with various solid tumors. The trial will enroll up to 45 patients and aims to evaluate safety, tolerability, and identify biomarkers ...
Coherus Oncology completed a public offering of 28.6 million shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of pipeline candidates, and for general corporate purposes. The offering was le...
Coherus Oncology priced an underwritten public offering of 28.6 million shares at $1.75 per share, generating approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of its PD-1 inhibitor LOQTORZI, advance clinical development of pipeline candidates, and for general corporate purposes. The of...
Coherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.
Coherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.
